Cargando…
Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model
Non-alcoholic steatohepatitis (NASH) is a common chronic liver disease with no decisive treatment. The sodium glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin was developed as a new oral hypoglycemic drug, which can improve NASH via an insulin-independent glucose-lowering effect by inhibiting...
Autores principales: | Morishita, Asahiro, Tadokoro, Tomoko, Fujihara, Shintaro, Iwama, Hisakazu, Oura, Kyoko, Fujita, Koji, Tani, Joji, Takuma, Kei, Nakahara, Mai, Shi, Tingting, Haba, Reiji, Okano, Keiichi, Nishiyama, Akira, Ono, Masafumi, Himoto, Takashi, Masaki, Tsutomu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863244/ https://www.ncbi.nlm.nih.gov/pubmed/35192632 http://dx.doi.org/10.1371/journal.pone.0261310 |
Ejemplares similares
-
Effect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cells
por: Nakahara, Mai, et al.
Publicado: (2022) -
MicroRNAs and Nonalcoholic Steatohepatitis: A Review
por: Morishita, Asahiro, et al.
Publicado: (2023) -
Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines
por: Takuma, Kei, et al.
Publicado: (2022) -
Galectin-9 suppresses the tumor growth of colon cancer in vitro and in vivo
por: Morishita, Asahiro, et al.
Publicado: (2021) -
Comprehensive analysis of circulating microRNAs as predictive biomarkers for sorafenib therapy outcome in hepatocellular carcinoma
por: Kohno, Tomoki, et al.
Publicado: (2020)